Introduction
============

It is well known that several hypothalamic circuits are involved in the regulation of feeding behavior and energy homeostasis, especially the arcuate nucleus and the paraventricular nucleus [@B1]. The melanocortin system plays an important role in the regulation of energy homeostasis [@B1]-[@B3]. The melanocortin-3 receptor (MC3R) was the third member of melanocortin receptor (MCR) family cloned, primarily expressed in brain, especially in the arcuate nucleus [@B4]-[@B8]. It is a rhodopsin-like G protein-coupled receptor (GPCR), primarily coupling to G~s~ protein to activate adenylyl cyclase that produces cAMP. Mouse genetic studies demonstrate that the MC3R regulates feeding efficiency and nutrient partitioning [@B9], [@B10]. Mice lacking both*Mc3r* and melanocortin-4 receptor (*Mc4r*) are more obese than mice lacking only *Mc4r* [@B9]. Recent studies report that MC3R acts as a mediator of the entrainment pattern of food intake to restricted feeding [@B11]-[@B13]. All these findings suggest that MC3R functions differently from MC4R, playing a non-redundant role in regulating energy homeostasis.

Loss-of-function mutations in *MC4R* are considered as pathogenic causes for human monogenic obesity, with more than 175 mutations identified [@B14]-[@B16] (reviewed in [@B17], [@B18]). However, few naturally occurring mutations in *MC3R* have been identified [@B19]-[@B25] (reviewed in [@B26]). The influence of these *MC3R* mutations on human obesity is controversial. The first *MC3R* mutation identified in two obese patients in Singapore is I183N, which results in complete loss-of-function [@B19], [@B27], [@B28] and co-segregates with childhood obesity [@B21]. Therefore I183N is considered a pathogenic mutation. Calton *et al*. reported that *MC3R* mutations are not associated with severe obesity in the two North American cohorts they studied, because the prevalence of *MC3R* mutations in obese subjects is not significantly different from that in control groups [@B23]. However, Mencarelli *et al.* reported that *MC3R* mutations with impaired function are significantly more prevalent in obese subjects of Italian and French origin [@B24]. Our previous studies showed that residues T280 and I335 play critical roles in different aspects of MC3R function, and T280S and I335S are potentially pathogenic for obesity [@B29], [@B30]. Collectively, the pathogenic role of MC3R in the development of obesity still needs further investigation. Therefore, in this study, detailed functional analyses were performed on 8 *MC3R* mutations (S17T, F82S, D158Y, V177I, L249F, R257S, L285V, and L299V) recently identified in North American cohorts [@B23], Italian and French subjects [@B24], and children and adolescents in Belgium [@B25] (Fig. [1](#F1){ref-type="fig"}).

It was suggested that the complexity of feeding behavior and long-lasting effects of melanocortins on energy homeostasis regulation involves the regulation of gene expression [@B31], especially through mitogen-activated protein kinases. MC4R has been reported to activate extracellular signal-regulated kinases 1 and 2 (ERK1/2) signaling cascade [@B31]-[@B33], which directly alter gene expression [@B34], [@B35]. We have reported that in addition to agonists, antagonists including inverse agonists also activate ERK1/2 in the MC4R [@B36]-[@B38] (reviewed in [@B39]). We also suggested that defects in basal or ligand-stimulated ERK1/2 signaling might cause obesity in patients harboring *MC4R* mutations where no other defect was identified previously [@B40].

Discordant data have been reported on whether the MC3R activates ERK1/2, with both supporting [@B13], [@B41], [@B42] and refuting [@B31] data reported. Moreover, whether naturally occurring mutations in the *MC3R* affects the two signaling pathways differentially was unknown. In this study, we investigated the effects of endogenous MC3R agonist α-melanocyte stimulating hormone (α-MSH) on ERK1/2 signaling in all 22 naturally occurring *MC3R* mutations reported so far in the literature, including 8 novel mutations functionally characterized in the present study and 14 mutations (S69C, A70T, I87T, N128S, M134I, I183N, L249V, A260V, M275T, T280S, A293T, L297V, I335S, and X361S), where the binding and G~s~-cAMP signaling have been previously characterized in detail [@B25], [@B27], [@B29], [@B30].

Materials and methods
=====================

Plasmid and peptides
--------------------

Human MC3R (hMC3R) cDNA with 3×HA tags at the N-terminus inserted in pcDNA3.1 vector was obtained from Missouri S&T University cDNA Resource Center (<http://www.cDNA.org/>, Rolla, MO). \[Nle^4^,D-Phe^7^\]-α-melanocyte stimulating hormone (NDP-MSH) was purchased from Peptides International (Louisville, KY) and iodinated as described previously [@B37]. α-MSH was purchased from Phoenix Pharmaceuticals (Belmont, CA).

Site-directed mutagenesis of the hMC3R mutants
----------------------------------------------

Mutations in hMC3R were generated by QuikChange^TM^ site-directed mutagenesis kit (Stratagene, La Jolla, CA) as described previously [@B43]. Plasmid DNAs were prepared by IsoPure DNA purification kits from Denville Scientific (Metuchen, NJ). Automated DNA sequencing was performed by the DNA Sequencing Facility of Cancer Research Center, University of Chicago (Chicago, IL)

Cells and transfections
-----------------------

Human embryonic kidney (HEK) 293T cells, purchased from American Type Culture Collection (Manassas, VA), were maintained at 37 °C in growth media (Dulbecco\'s Modified Eagle\'s Medium (DMEM) supplemented with 10% newborn calf serum, 10 mM Hepes, 100 IU/ml of penicillin, 100 μg/ml of streptomycin, 50 μg/ml of gentamicin, and 0.25 μg/ml of amphotericin B), with 5% CO~2~. Cells were plated on gelatin-coated 35mm 6-well clusters from Corning (Corning, NY) and transient transfection was done using the calcium precipitation method [@B44] at 50-70% confluency. Cells were incubated for approximately 48 h after transfection before assayed.

Ligand binding assay
--------------------

Ligand binding assays were performed as described previously [@B43]. Briefly, 48 h after transfection, cells were washed twice with warm Waymouth\'s MB752/1 media (Sigma-Aldrich, St. Louis, MO) containing 1 mg/ml bovine serum albumin (BSA) (referred to as Waymouth/BSA). Fresh Waymouth/BSA was added to each well, incubated with ^125^I-NDP-MSH (100,000 cpm) with or without different concentrations of unlabeled NDP- or α-MSH at 37 °C for 1 h. The total volume in each well was 1 ml. The final concentrations of unlabeled ligands are indicated in the figures. After incubation, cells were placed on ice and washed twice with cold Hank\'s balanced salt solution (Sigma-Aldrich) containing 1 mg/ml BSA to terminate the reaction. Then 100 μl of 0.5 N NaOH were added to each well to solubilize cells. Cell lysates were collected using cotton swabs and counted in a γ-counter. All determinations were performed in duplicate. The receptor occupancy (RO) and IC~50~ values were calculated by GraphPad Prism 4.0 (San Diego, CA) [@B45].

Ligand stimulated cAMP signaling
--------------------------------

HEK293T cells transfected with WT or mutant hMC3Rs were washed twice with warm Waymouth/BSA 48 h after transfection. Then fresh Waymouth/BSA containing 0.5 mM isobutylmethylxanthine (Sigma-Aldrich) was added and cells were incubated at 37 °C for 15 min. Then, either Waymouth/BSA alone or different concentrations of ligands were added and cells were incubated for another 1 h at 37 °C. Cells were then placed on ice and intracellular cAMP was extracted with 0.5 N percholoric acid containing 180 μg/ml theophylline. The cAMP levels were measured by radioimmunoassay [@B46], [@B47]. All determinations were performed in triplicate. Maximal responses (Rmax) and EC~50~ values were calculated using GraphPad Prism 4.0.

Quantification of hMC3R expression by flow cytometry
----------------------------------------------------

Flow cytometry was performed as previously described [@B45], [@B48], [@B49]. Briefly, HEK293 cells were transiently transfected with 1 μg plasmid in 2ml media for each well in 6-well cluster. After 48 h incubation, cells were detached in filtered phosphate buffered saline for immunohistochemistry (PBS-IH) (137 mM NaCl, 2.7 mM KCl, 1.4 mM KH~2~PO~4~, 4.3 mM Na~2~HPO~4~, pH 7.4), and then precipitated by centrifugation at 500 × g. Cells were fixed using PBS-IH containing 4% paraformaldehyde for 30 min. 1% Triton X-100 treatment for 4 min was applied to permeabilize cells for measuring total receptor expression (this step was omitted when measuring cell surface expression). Cells were blocked with PBS-IH containing 5% BSA for 1 h and then immunostained with primary anti-HA.11 antibody (1:50, Covance, Princeton, NJ) in PBS-IH containing 0.5% BSA for 1 h. Cells were washed with PBS-IH containing 0.5% BSA and the secondary Alexa Fluor 488-conjugated goat anti-mouse IgG (1:2000, Invitrogen, Carlsbad, CA) in PBS-IH containing 0.5% BSA were added under dim light. After 1 h incubation, cells were washed and resuspended in PBS-IH with 0.5% BSA. The expression of mutant hMC3Rs in 10,000 cells from each transfection was quantified by an Accuri flow cytometer with a 488-nm wavelength laser. Cells transfected with pcDNA3.1 empty vector was used to correct for background staining. Mutant expression levels were calculated as percentage of WT hMC3R expression using the following formula: (mutant - empty vector) / (WT - empty vector) × 100% [@B45], [@B48], [@B49].

ERK1/2 phosphorylation assay
----------------------------

The phosphorylated ERK1/2 (pERK1/2) levels were measured by Western blot as described before [@B36]-[@B38], [@B40]. Briefly, HEK293T cells were plated on gelatin-coated 100 mm dishes and transfected with WT or mutant hMC3R constructs. Approximately 24 h after transfection, cells were starved overnight, and then treated with either 10^-5^M α-MSH or Waymouth/BSA alone for 5 min. Proteins were extracted in lysis buffer containing phosphatase and protease inhibitors, separated by 10% SDS-PAGE, and transferred onto PVDF membrane. pERK1/2 and β-tubulin levels were detected with primary rabbit anti-pERK1/2 antibody (1:1000 \~ 1:2000, Cell Signaling Technology, Beverly, MA) and mouse anti-β-tubulin antibody (1:5000 \~ 1:10,000, Developmental Studies Hybridoma Bank at University of Iowa, Iowa City, IA) in Tris-buffered saline with Tween-20 containing 5% BSA, respectively. Then the membranes were incubated with secondary horseradish peroxidase-conjugated donkey anti-rabbit antibody (1:1000 \~ 1:2000, Jackson ImmunoResearch Laboratories, West Grove, PA) and horseradish peroxidase-conjugated donkey anti-mouse antibody (1:5000, Jackson ImmunoResearch Laboratories) in milk at room temperature for 2 h. PVDF membranes were visualized by enhanced chemiluminescence reagent (Pierce, Rockford, IL) and the signals were quantified using ImageJ 1.44 (National Institutes of Health, Bethesda, MD). ERK1/2 phosphorylation levels were expressed as a ratio of pERK1/2 over β-tubulin.

Statistical analyses
--------------------

Student\'s *t*-test was used to determine the significance of differences in the expression, ligand binding, cAMP signaling and pERK1/2 levels between WT and mutant hMC3Rs. Statistical analysis was carried out using GraphPad Prism 4.0.

Results
=======

Quantification of the expression of the novel mutant hMC3Rs using flow cytometry
--------------------------------------------------------------------------------

HEK293T cells, which do not express endogenous MC3R, were used as a mammalian expression system in the present study. To study the localization of the novel mutant hMC3Rs and to quantitate their expression levels, flow cytometry was performed. The data of non-permeabilized cells showed that all the mutants had similar cell surface expression as the WT hMC3R except F82S, which had significantly decreased cell surface expression to about 60% of the WT hMC3R (Fig. [2](#F2){ref-type="fig"}A). All mutants had similar total protein expression levels as the WT hMC3R as shown in permeabilized cells (Fig. [2](#F2){ref-type="fig"}B).

Ligand binding properties of the novel mutant hMC3Rs
----------------------------------------------------

Competitive ligand binding assays were performed with the superpotent analog NDP-MSH [@B50] and the endogenous agonist α-MSH as competitors. When NDP-MSH was used, mutants F82S, D158Y and L299V had negligible specific binding (Fig. [3](#F3){ref-type="fig"}A), and their IC~50~ values could not be determined. All the other novel mutants had similar IC~50~s as the WT hMC3R (Table [1](#T1){ref-type="table"}). When the endogenous agonist α-MSH was used as the competitor (Fig. [3](#F3){ref-type="fig"}B), the IC~50~ of F82S, D158Y and L299V could not be determined either. Mutants S17T, L249F and L285V had significantly increased IC~50~s (decreased binding affinity). The other two mutants had similar IC~50~s as the WT hMC3R (Table [2](#T2){ref-type="table"}).

As shown in Table [1](#T1){ref-type="table"}, F82S, D158Y and L299V were almost completely devoid of specific binding. R257S exhibited significantly decreased RO to about 70% of WT hMC3R. All the other new mutants had similar RO as the WT hMC3R (Table [1](#T1){ref-type="table"}).

cAMP signaling activity of the novel mutant hMC3Rs in response to NDP-MSH or α-MSH stimulation
----------------------------------------------------------------------------------------------

To investigate whether these eight new missense mutations would affect MC3R signaling, the intracellular cAMP levels stimulated by different ligands were measured. First, cAMP signaling property in response to NDP-MSH was tested. Fig. [4](#F4){ref-type="fig"}A showed the result of one representative experiment. For mutants F82S and D158Y, their EC~50~s could not be determined. L299V had significantly increased EC~50~. S17T and V177I had similar maximal signaling as the WT hMC3R, while the other mutants had significantly reduced maximal signaling, especially D158Y, which was completely inactive (Table [1](#T1){ref-type="table"}).

Then the cAMP signaling property was investigated with α-MSH as the ligand (Fig. [4](#F4){ref-type="fig"}B). Similarly, EC~50~ of mutants F82S and D158Y could not be determined. D158Y was totally devoid of cAMP signaling. Three mutants (F82S, L285V and L299V) displayed significantly decreased maximal signaling compared to the WT hMC3R. The signaling properties of the remaining mutants were similar to that of the WT hMC3R (Table [2](#T2){ref-type="table"}).

Different from the MC4R, the MC3R has little constitutive activity [@B29]. In the current study, none of the 8 novel mutants had increased basal cAMP levels. Indeed, two mutants (D158Y and L285V) had significantly decreased basal activity compared to the WT hMC3R (Table [1](#T1){ref-type="table"}).

ERK1/2 signaling efficacies to endogenous agonist α-MSH
-------------------------------------------------------

HEK293T cells transiently transfected with all the 22 naturally occurring missense mutations in *MC3R* identified to date, excluding the two single nucleotide polymorphisms (K6T and I81V), were used to explore the effect of endogenous MC3R agonist α-MSH on ERK1/2 signaling. We found that α-MSH acted as an agonist for MAPK pathway, resulting in a significantly increased pERK1/2 level with a 5.6-fold maximal response for the WT hMC3R (Fig. [5](#F5){ref-type="fig"}). Fourteen mutants (S69C, A70T, F82S, V177I, I183N, L249F, L249V, R257S, A260V, M275T, L285V, A293T, L299V and I335S) had significant activation of ERK1/2 upon α-MSH stimulation for 5 min (Fig. [5](#F5){ref-type="fig"} and Table [3](#T3){ref-type="table"}). Although not statistically significant, two mutants (S17T and X361S) had more than 5-fold increase in pERK1/2 levels. The other six mutants (I87T, N128S, M134I, D158Y, T280S, and A297V) had no significant change in pERK1/2 levels. These data demonstrated that α-MSH, known as an agonist for MC3R in the conventional G~s~-cAMP pathway, exhibited agonist activity causing significantly elevated pERK1/2 levels for WT and some mutant hMC3Rs. α-MSH caused balanced agonism in G~s~-cAMP and ERK1/2 pathways for WT and 15 mutant hMC3Rs, while for the other 7 mutants, α-MSH induced divergent activities (Table [3](#T3){ref-type="table"}).

In addition, the basal pERK1/2 levels of the majority of mutant hMC3Rs were similar as that of WT hMC3R. However, S17T and D158Y had significantly decreased basal pERK1/2 levels, while mutant I183N exhibited significantly increased basal pERK1/2 (Fig. [6](#F6){ref-type="fig"}), indicating constitutive activity in the ERK1/2 signaling cascade.

Discussion
==========

In this study, we first performed detailed functional characterization of 8 new naturally occurring *MC3R* mutations (S17T, F82S, D158Y, V177I, L249F, R257S, L285V, and L299V). Among these mutations, S17T, D158Y, V177I, and L299V were identified in unrelated obese carriers; F82S, R257S, and L285V were identified in lean subjects; L249F was identified in both obese and lean subjects [@B23]-[@B25]. All 8 mutants were expressed on the cell surface, but F82S had significantly decreased cell surface expression compared to the WT hMC3R (Fig. [2](#F2){ref-type="fig"}A). All mutants had similar total expression levels as the WT hMC3R (Fig. [2](#F2){ref-type="fig"}B). These results showed that F82S was partially retained intracellularly, which is the common cause for the majority of GPCR mutations leading to human diseases [@B51], [@B52], and most of the*MC4R* mutations belong to this class [@B53].

In addition to partial intracellular retention, F82S was expressed on the cell surface. Ligand binding and cAMP signaling data showed that it had significant defects in both ligand binding and agonist-stimulated cAMP generation (Figs. [3](#F3){ref-type="fig"}-[4](#F4){ref-type="fig"} and Tables [1](#T1){ref-type="table"}-[2](#T2){ref-type="table"}). A naturally occurring mutation in *MC4R* identified from obese patients with binge eating disorder substitutes the cognate Phe with Leu at codon 51, leading to unchanged ligand binding and cAMP signaling [@B54]. Therefore changing Phe to Leu, which has small change in size, does not affect the MC4R function [@B54], whereas changing hydrophobic Phe to Ser with polar side chain significantly impaired MC3R trafficking and function, suggesting that the hydrophobic feature of codon 82 might be of importance for MC3R trafficking, ligand binding and cAMP signaling.

D158Y was almost totally devoid of ligand binding and cAMP signaling (Figs. [3](#F3){ref-type="fig"}-[4](#F4){ref-type="fig"} and Tables [1](#T1){ref-type="table"}-[2](#T2){ref-type="table"}). The cognate D126 in the MC4R is important for ligand-receptor interaction [@B55] and our previous site-directed mutagenesis study demonstrated that D158 in the MC3R plays an important role in different aspects of receptor function [@B45]. In that study, mutating Asp to Glu or Gln at codon 158 resulted in undetectable ligand binding and cAMP signaling in response to NDP-MSH stimulation, and mutating Asp to Glu led to significantly decreased cell surface expression [@B45]. Combined with the results in the present study, we conclude that D158 was important for receptor expression, ligand binding and cAMP signaling. D158Y might be the pathogenic cause to obesity for the patient harboring the mutation.

L299V had similar expression (Fig. [2](#F2){ref-type="fig"}) but significantly reduced ligand binding and cAMP signaling compared to the WT hMC3R (Figs. [3](#F3){ref-type="fig"}-[4](#F4){ref-type="fig"} and Tables [1](#T1){ref-type="table"}-[2](#T2){ref-type="table"}). Previously, L299V was reported to result in decreased cell surface expression and impaired function of this mutant, suggested to be due to intracellular retention [@B25]. Zegers *et al.* used enhanced green fluorescent protein (EGFP)-MC3R fusion proteins to investigate the localization [@B25]. The addition of GFP can interrupt the intracellular trafficking of receptors [@B21]. This might be the possible explanation for the abnormal cell surface expression of L299V in the original publication.

According to the alignment of the amino acid sequences of MCRs, the Leu at codon 299 in MC3R is a conserved residue among MCRs (except melanocortin-2 receptor). This residue corresponds to L265 in MC4R [@B3] and is considered to probably contribute to a hydrophobic binding pocket for agonist to dock [@B55]. The substitution of L265 in MC4R dramatically alters the affinity and potencies of NDP-MSH and two other agonists [@B56]. L299 might also be important for ligand binding and subsequent cAMP signaling in the MC3R.

Although the expression (Fig. [2](#F2){ref-type="fig"}) and binding (Table [1](#T1){ref-type="table"}) of L285V were similar to the WT hMC3R, it had significantly decreased maximal cAMP signaling (Tables [1](#T1){ref-type="table"}-[2](#T2){ref-type="table"}), suggesting that this was a cAMP signaling-defective mutant. Mutants L249F and R257S had significantly decreased cAMP generation in response to NDP-MSH but not α-MSH (Tables [1](#T1){ref-type="table"}-[2](#T2){ref-type="table"}). Hence the defect in cAMP signaling pathway for these two mutants was ligand-dependent. In our previous study, we showed another naturally occurring mutation, L249V, has decreased cell surface expression but ligand binding and cAMP signaling is not affected [@B30]. Altogether, the combined results indicated that L249 might be important for MC3R expression and cAMP signaling.

We also studied ERK1/2 signaling of all 22 naturally occurring *MC3R*mutations upon α-MSH stimulation. We found that α-MSH induced significant activation of ERK1/2 in the WT hMC3R (Fig. [5](#F5){ref-type="fig"}), consistent with previous studies when the WT MC3R was stimulated with either NDP-MSH or D-Trp^8^-γ-MSH as well as in mouse dorsal medial nucleus and ventromedial nucleus [@B13], [@B41], [@B42], although not consistent with another report [@B31]. The reason for this discrepancy is not clear.

Among the 22 mutations we studied, α-MSH exhibited balanced activity in G~s~-cAMP and ERK1/2 cascades in 15 mutants. D158Y and T280S could not activate any of the two signaling pathways (Table [3](#T3){ref-type="table"} and Fig. [5](#F5){ref-type="fig"}). The other 7 mutants either selectively increased cAMP generation, or selectively activated ERK1/2 phosphorylation upon α-MSH stimulation (Table [3](#T3){ref-type="table"}). α-MSH selectively elevated cAMP production for I87T, N128S, M134I, and L297V without significant activation of ERK1/2 cascade, whereas α-MSH selectively induced ERK1/2 phosphorylation for F82S, I183N, and I335S, without increasing cAMP production. Therefore these mutant receptors were biased receptors, in which agonist only stabilizes a restricted subset of conformations activating one signaling pathway [@B57]-[@B59]. In the literature, there are only a few examples of biased receptors from naturally occurring mutations in GPCRs, including the melanocortin-1 receptor and MC4R [@B40], [@B60]-[@B64]. Our data add to this expanding field.

We also found that I183N displayed significantly increased basal pERK1/2 level (Fig. [6](#F6){ref-type="fig"}), suggesting constitutive activity in basal pERK1/2 signaling. Traditionally, the constitutive activity of GPCRs is mainly associated with G protein-mediated signaling [@B32], [@B65]. Unlike the MC4R, the WT hMC3R has low constitutive activity [@B29]. No constitutively active naturally occurring mutations in *MC3R* have been reported. Only one laboratory-generated mutation of MC3R (F347A) was observed to have increased basal cAMP level [@B47]. However, in the current study, we found I183N, the first *MC3R* mutation considered to have causal relationship to human obesity, had constitutive ERK1/2 activity. Very few reports exist in the literature on constitutive activation of ERK1/2 by GPCRs. A naturally occurring α~1a~-adrenergic receptor variant constitutively activates ERK pathway with physiological consequences [@B66], [@B67]. Similarly, we observed constitutive ERK1/2 signaling in naturally occurring and lab-generated MC4R mutants [@B37], [@B38], [@B40] (reviewed in [@B39]). Our current findings added a new layer of the understanding of structure-function relationship of mutant hMC3Rs. Constitutive ERK activity could regulate multiple functions including proliferation and differentiation [@B68], [@B69]. The *in vivo* relevance of the constitutive ERK activity in I183N deserves further investigation.

In summary, detailed functional studies of 8 new naturally occurring mutations in *MC3R* were performed. D158Y and L299V might be pathogenic for human obesity. F82, D158, L249 and L299 played important roles in different aspects of MC3R functions. The ERK1/2 signaling pathway of WT and mutant hMC3Rs was explored. The results showed that WT hMC3R activated ERK1/2 signaling upon stimulation by α-MSH, and that some mutant hMC3Rs were biased to different intracellular signaling cascades upon α-MSH stimulation, contributing to a better understanding of MC3R pharmacology.

The β-tubulin antibody was obtained from Developmental Studies Hybridoma Bank, developed under the auspices of NICHD and maintained by University of Iowa Department of Biology. We thank Allison Church Bird at the Auburn University College of Veterinary Medicine Flow Cytometry Core Facility for her assistance with flow cytometry experiments. This research was funded by the National Institutes of Health grant R15DK077213, American Diabetes Association Grant 1-12-BS212, Auburn University Intramural Grant Program, and Animal Health and Diseases Research Program and Interdisciplinary Grant from College of Veterinary Medicine, Auburn University. Fan Yang was supported by the fellowship from China Scholarship Council of the People\'s Republic of China.
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![Schematic model of the hMC3R with the mutations investigated in this study highlighted. Mutations that induce biased signaling are also indicated.](ijbsv11p0423g001){#F1}

![Quantitative measurement of cell surface (A) or total (B) expression of the novel mutant hMC3Rs by flow cytometry. In panel A, cell surface expression of mutant hMC3Rs were expressed as percentage of WT hMC3R cell surface expression after correction of the nonspecific staining in cells transiently transfected with empty vector. Data were mean ± SEM of 4-8 experiments. Star (\*) indicates significantly different from WT hMC3R, *P* \< 0.05. In panel B, total expression of mutant hMC3R were expressed as percentage of WT hMC3R total expression level after correction for the nonspecific staining. Data were mean ± SEM of at least four experiments.](ijbsv11p0423g002){#F2}

![Ligand binding properties of the new mutant hMC3Rs with NDP-MSH (A) and α-MSH (B) as the ligand. Different concentrations of unlabeled NDP-MSH or α-MSH competitively displaced the binding of ^125^I-NDP-MSH to hMC3Rs on intact cells. Results are expressed as percentage of WT binding ± range from duplicate determinations within one experiment. All experiments were performed at least three times.](ijbsv11p0423g003){#F3}

![Cyclic AMP signaling properties of the new mutant hMC3Rs with NDP-MSH (A) and α-MSH (B) as the ligand. Intracellular cAMP concentrations were measured as described in Materials and Methods. Results are expressed as the mean ± SEM of triplicate determinations from one experiment. All experiments were performed at least three times.](ijbsv11p0423g004){#F4}

###### 

The effect of α-MSH on ERK1/2 signaling in mutant hMC3Rs. HEK293T cells were stimulated with or without 10^-5^M α-MSH for 5 min. ERK1/2 phosphorylation was measured as described in Materials and Methods. Panel A showed the representative image of one experiment. Panel B showed the densitometry results of ERK1/2 phosphorylation of the WT and mutant hMC3Rs. Results are expressed as the percentage of the value obtained in non-stimulated cells transfected with the WT hMC3R. Shown are mean ± SEM of at least four experiments. Star (\*) indicates significantly different from WT basal level, *P* \< 0.05.
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![Basal pERK1/2 signaling of mutant hMC3Rs. Results are expressed as percentage of WT basal pERK1/2 level. Shown are mean ± SEM of at least four experiments. Star (\*) indicates significantly different from WT hMC3R, *P* \< 0.05.](ijbsv11p0423g007){#F6}

###### 

Binding and signaling properties of the 8 new mutant hMC3Rs with NDP-MSH as the ligand.

  hMC3R   NDP-MSH binding   Basal signaling (% WT)   NDP-MSH-stimulated cAMP                     
  ------- ----------------- ------------------------ ------------------------- ----------------- ------------------
  WT      6.45 ± 0.87       100 ± 0                  100 ± 0                   1.28 ± 0.49       100 ± 0
  S17T    5.73 ± 0.48       136.00 ± 15.43           107.50 ± 24.68            1.24 ± 0.68       81.87 ± 17.35
  F82S    ND                8.07 ± 1.45^c^           84.05 ± 19.86             ND                22.99 ± 2.26^c^
  D158Y   ND                ND                       54.05 ± 8.81^b^           ND                ND
  V177I   4.33 ± 1.61       82.96 ± 11.96            88.01 ± 21.52             0.62 ± 0.14       61.81 ± 10.02
  L249F   7.74 ± 1.99       128.39 ± 23.49           69.48 ± 20.70             4.98 ± 2.54       50.02 ± 2.74^b^
  R257S   5.88 ± 0.12       73.38 ± 8.36^a^          78.80 ± 13.97             3.26 ± 1.62       44.05 ± 12.03^a^
  L285V   6.07 ± 1.02       93.68 ± 13.78            52.40 ± 11.86^b^          5.76 ± 2.64       29.71 ± 3.22^b^
  L299V   ND                8.65 ± 1.51^c^           78.55 ± 15.31             14.84 ± 4.29^a^   38.53 ± 5.31^b^

^a^Significantly different from the WT hMC3R, *P* \< 0.05.

^b^ Significantly different from the WT hMC3R, *P* \< 0.01.

^c^ Significantly different from the WT hMC3R, *P* \< 0.001.

ND, not detected.

The data are expressed as the mean ± SEM of at least three independent experiments for IC~50~, EC~50~, and Rmax, and at least six independent experiments for RO and basal signaling. The basal cAMP was 36.88 ± 5.89 pmol/10^6^ cells and the Rmax was 2526.00 ± 502.11 pmol cAMP/10^6^ cells for the WT hMC3R.

###### 

Binding and signaling properties of the 8 new mutant hMC3Rs with α-MSH as the ligand.

  hMC3R   α-MSH binding          α-MSH-stimulated cAMP   
  ------- ------------------- -- ----------------------- ------------------
  WT      28.49 ± 2.86           2.91 ± 1.42             100.00
  S17T    50.89 ± 4.58^a^        13.92 ± 11.42           102.74 ± 10.19
  F82S    ND                     ND                      21.18 ± 6.31^b^
  D158Y   ND                     ND                      ND
  V177I   51.28 ± 10.25          3.10 ± 1.96             80.18 ± 11.26
  L249F   58.66 ± 2.57^b^        1.31 ± 0.55             55.99 ± 13.71
  R257S   40.81 ± 3.79           3.62 ± 0.35             61.78 ± 16.14
  L285V   124.86 ± 20.05^b^      18.90 ± 10.64           40.95 ± 11.19^a^
  L299V   ND                     115.71 ± 50.16          29.03 ± 8.73^a^

^a^ Significantly different from the WT hMC3R, P \< 0.05.

^b^ Significantly different from the WT hMC3R, P \< 0.01.

ND, not detected.

The data are expressed as the mean ± SEM of at least three independent experiments. The Rmax was 2188.03 ± 638.76 pmol cAMP/10^6^ cells for the WT hMC3R.

###### 

The effect of α-MSH on cAMP and pERK1/2 signaling of WT and mutant hMC3Rs.

  hMC3R   α-MSH         
  ------- ------- ----- -----
  WT      ↑       ↑     No
  S17T    ↑       ↑     No
  S69C    ↑       ↑     No
  A70T    ↑       ↑     No
  F82S    ---     ↑     Yes
  I87T    ↑       ---   Yes
  N128S   ↑       ---   Yes
  M134I   ↑       ---   Yes
  D158Y   ---     ---   No
  V177I   ↑       ↑     No
  I183N   ---     ↑     Yes
  L249F   ↑       ↑     No
  L249V   ↑       ↑     No
  R257S   ↑       ↑     No
  A260V   ↑       ↑     No
  M275T   ↑       ↑     No
  T280S   ---     ---   No
  L285V   ↑       ↑     No
  A293T   ↑       ↑     No
  L297V   ↑       ---   Yes
  L299V   ↑       ↑     No
  I335S   ---     ↑     Yes
  X361S   ↑       ↑     No

"↑": Denotes increased activity compared to the basal level. "−": denotes no significant changes between basal and maximal signaling levels. "Bias" column is designed to demonstrate whether α-MSH-stimulated cAMP and pERK1/2 signaling pathways were divergent. "Yes" denotes biased activation of either signaling pathway; "No" denotes balanced cAMP and pERK1/2 signaling.
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